Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Unraveling the natural complexity of protein secretion to optimise novel robust yeast strains (ProteoYeast)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Belgium
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2022-11-01
End date: 2024-10-31
Duration (months): 24.0
Total project cost (EUR): 175920.0
EU funding (EUR): 175920.0
Participants: 1
Project status: SIGNED

Protein secretion is a universal trait among organisms, involving multiple steps of quality control, sorting, trafficking, and export; as well as various organelles. Numerous pressing challenges faced by society can be addressed by thoroughly understanding protein secretion. Disease mechanisms can be elucidated, new antimicrobials can be discovered, and high-value proteins can be produced. However, exactly because of its complexity, a full mechanistic understanding of protein secretion is still lacking, impeding full exploitation. The yeast Saccharomyces cerevisiae is a promising model organism for studying protein secretion and is also a major expression host for industrial heterologous protein production. So far research has only focused on a few lab strains, that are inefficient protein secretors and that do not fully represent this yeast’s natural biodiversity. My preliminary data show that properties considered to be optimal in lab strains often are inferior to those observed in some other, more ‘wild’ yeast. Herein, I propose that natural S. cerevisiae strains can have more efficient protein production and secretion pathways and that the responsible alleles can be identified and exploited creating a robust protein-producing strain. In ProteoYeast, I will combine my skills in omics analyses and systems biology with the host lab’s QTL mapping expertise, unique yeast collection (>1200 strains) and advanced robotic systems to address the existing knowledge gap. This work will be divided into three parts: 1) High-throughput investigation of the natural biodiversity for protein secretion in a high-throughput manner; 2) ‘Round Robin’ QTL approach to identify novel alleles affecting protein secretion; and 3) development of robust strains for high-titer secretion of added-value proteins. Today’s urgent demand for a sustainable bio-based economy, combined with progress in laboratory automation and systems biology make this project timely and fitting to societal needs

Keywords: genome variability and evolution biodiversity secretion systems biology quantitative trait locus
IN-situ Thermometry gUidance In phoTomedicine (INTUIT)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Italy,Ireland,Hungary,Germany
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2024-06-01
End date: 2026-11-30
Duration (months): 30.0
Total project cost (EUR): 235737.6
EU funding (EUR): 235737.6
Participants: 5
Project status: SIGNED

INTUIT project aims to pioneer the development of photonic-based spectroscopy and thermometry methods, namely Hyperspectral imaging (HSI) and optical sensing with Fibre Bragg Gratings (FBG), into clinical solutions to visualize and differentiate tissue experiencing coagulative necrosis and/or hyperthermia from normal healthy tissue during tumor removal involving thermal ablation. This technology will improve surgical guidance, minimizing the destruction of surrounding healthy tissue while achieving a complete tumor resection. Four Work Packages (WPs) will be implemented throughout the Action: WP1 to study endogenous concentrations of optical biomarkers useful to differentiate the ablation margins. WP2 to develop a tissue phantom to recreate the thermal gradients and optical properties of the main tissue ablation zones (this phantom will be used to calibrate and validate the HSI and FBG systems). WP3 to conduct observational animal studies and collect data in-situ on animals undergoing oncology treatment with laser ablation; and WP4 in synergy with all WPs above, dedicated to data processing and development of algorithms for margin detection and to guarantee appropriate data collection, processing and storing. The work plan will bring HSI and FBG technologies to TRL 4 by month 24 of the Action. The next 6 months, involve work at a non-academic host to advance towards TRL 5, and further plan strategies and partnerships to push the proposed technologies towards commercialization with the ultimate goal of improving veterinary and human healthcare. WP1 and WP2 will be conducted at the Politecnico di Milano under the supervision of Prof. Saccomandi who has expertise in thermometry. The animal studies from WP3 will be supervised by Dr. Vajdovich (expert in veterinary pathology and oncology) at the University of Veterinary Medicine Budapest. The data processing will be supervised by Dr. Bocklitz from Leibniz-IPHT whos research is dedicated to photonic data life-cycle.

Keywords: photonic based thermometry hyperspectral imaging fiber bragg grating optical and thermal tissue phantom
Investigating the brain substrates underlying higher-order social learning (SocialLearn)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Spain
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2025-08-01
End date: 2027-07-31
Duration (months): 24.0
Total project cost (EUR): 194074.56
EU funding (EUR): 194074.56
Participants: 1
Project status: SIGNED

Adapting behavior based on context and past experiences is crucial for social animals. Social cues are key in this process as they help animals learn about their environment in relation to other members of their species. Animals learn to associate sensory cues (conditioned stimuli, CS), such as sounds or lights, with salient stimuli (unconditioned stimuli, US) through higher-order conditioning, also known as mediated learning (ML). Recent studies have implicated two brain areas, the hippocampus (HPC) and basolateral amygdala (BLA), in ML. However, how these areas contribute to socially induced ML and which specific cell types are involved remains unknown. The SocialLearn project aims to systematically investigate the neural mechanisms underlying higher-order conditioning using social cues. Specifically, the project will focus on the HPC and BLA and their roles in socially induced ML. I will develop novel higher-order conditioning paradigms that incorporate social cues as unconditioned stimuli, enabling the study of ML in social contexts. Next, I will examine how different cell types in the HPC and BLA encode social higher-order associations by using dual-color, dual-site fiber photometry to record neural activity. Finally, I will manipulate excitatory and inhibitory neurons in these regions to determine their roles in the formation and expression of ML. This approach, combined with unsupervised behavioral analysis, will allow me to investigate ML in social settings, reveal the activity patterns of specific neuronal populations in the HPC and BLA, and clarify their roles in this complex cognitive process. If successful, the project will provide new tools for studying higher-order conditioning in social contexts, deepen our understanding of how social experiences shape behavior, and offer insights into psychotic-like experiences. SocialLearn will also help me develop critical scientific and leadership skills, preparing me for future research leadership roles.

Keywords: social behavior,higher order conditioning,hippocampus,amygdala,neural circuits
GUIDE-AI – Guiding your treatment with current evidence (GUIDE-AI)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Public-private partnerships
Destination: Innovative Health Initiative
Action type: Research and Innovation actions
Partnership: IHI (JU-JTI)
Countries involved: Germany,Italy,Netherlands,Slovenia,Estonia,United Kingdom,Israel,Switzerland
Call: Boosting innovation for peopled centred integrated healthcare solutions (HORIZON-JU-IHI-2025-09-single-stage, 2025)
Start date: 2026-01-01
End date: 2029-12-31
Duration (months): 48.0
Total project cost (EUR): 8714418.0
EU funding (EUR): 4895668.0
Participants: 19
Project status: SIGNED

Today, chronic lung, heart, and kidney diseases constitute a large proportion of chronic illness in Europe’s population, with nearly 85% of deaths in the EU due to chronic diseases. Guideline-directed medical therapy is evidence-based and the cornerstone of pharmacological therapy for patients with chronic illness. Yet, a large number of patients are not receiving all medications as recommended given the length and complexity of guidelines. The ambition of GUIDE-AI is to leverage generative AI to increase guideline adherence of chronically ill patients in Europe. GUIDE-AI will be developed as a blueprint on three indications: Chronic obstructive pulmonary disease, chronic heart failure, and chronic kidney disease. This setup can be expanded to other chronic diseases where clinical practice guidelines exist or be updated with the new guideline once published. GUIDE-AI has three objectives: OBJ-A[people-centricity]: GUIDE-AI integrates the perspectives of patients, physicians, healthcare administrators, and payers, addressing both inpatient and outpatient care and covering the full treatment continuum—from diagnosis and therapy initiation to long-term monitoring and treatment adjustments. OBJ-B [Innovate & Integrate]: GUIDE-AI computer scientists and clinicians will develop the technical set-up of the guideline navigators including benchmarking and red teaming on retrospective data. OBJ-C [evaluate in real world]: GUIDE-AI will evaluate the guideline navigators in a real-world evaluation study in a 2-arms randomized design. The primary outcomes are (1) the percentage of guideline-conform therapies and (2) the number of patients whose medication changed after the LLM-intervention. Taken together, GUIDE-AI is a public-private partnership uniquely positioned to bring together private partners with leading academic institutions to advance beyond existing solutions to increase guideline-directed medical therapy by employing generative AI, making the latest evidence actionable. The impact will be demonstrated across multiple diseases, sectors, countries and languages.

Keywords: artificial intelligence,large language models,guideline directed medical therapy,chronic obstructive pulmonary disease,heart failure,chronic kidney disease
SET PLAN CONFERENCE 2022 (SET Plan)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Cluster 5 other
Destination: Other Climate, Energy and Mobility destinations
Action type: Coordination and support actions
Countries involved: Czechia
Call: Support for the SET Plan Conference 2022 (HORIZON-CL5-2022-SETPLAN-IBA, 2022)
Start date: 2022-07-01
End date: 2022-12-31
Duration (months): 6.0
Total project cost (EUR): 246000.0
EU funding (EUR): 196800.0
Participants: 1
Project status: CLOSED

This is a proposal to host SET Plan Conference 2022 in the Czech Republic during the Czech Presidency of the EU. The Conference will take place in Prague on 9 - 10 November 2022. The programme is dived into several thematic sessions dedicated to e.g. low-carbon sources, industry, buildings, hydrogen, CCS etc. There will be a high-level panel where we expect the attendance of Commissioners Simson and Gabriel. Minister of Industry and Trade will also be present. The first day will be closed by an informal dinner. The Conference should promote research and innovation in the EU and enable discussions among different researchers. A result should be recommendations on the future orientation of the EU research and innovation programmes.
CORPORATE ZERO-EMISSION, LOW-COST AND HIGH-SPEED POINT-TO-POINT TRANSPORT BASED ON AN ELEVATED, MODULAR AND AI-DRIVEN PASSIVE RAIL NETWORK (SMART RAIL TRANSPORT)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Germany
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Ottobahn is presenting a paradigm shift in how corporate transportation networks are designed and operated. We are combining the lean structure of elevated rail networks upon which autonomous and electric gondolas operate with AI-driven fleet management technologies that enable highly efficient point-to-point travel. While operating 5-10 m above ground, the gondola system is fully compatible with existing corporate structures since no land usage is required. Solar energy and electric drives assure zero-emission transport and, due to the passive rail technology, maximum longevity and safety are achieved. Ottobahn is highly versatile with a key use case in corporate cargo and passenger transport. For lean and efficient goods transport across industrial premises or facilities. Ottobahn transforms corporate transport into an emission-free, low-cost and convenient experience.
ACD856 - Revolutionising Alzheimer’s disease treatment through disease-modifying and cognitive-enhancing therapy (NeuroRestore ACD856)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Sweden
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Alzheimer’s disease (AD) is a devastating neurodegenerative disorder affecting millions worldwide, with no curative and cognitive-enhancing treatment available. Every 5 seconds a new person is diagnosed with AD and the number of AD patients in Europe is expected to almost double by 2050, rising from about 7.8 to over 14 million. The economic burden is immense, with dementia care costs exceeding €200 billion annually in Europe, surpassing those of oncology and cardiovascular diseases. AlzeCure Pharma is addressing this critical need with ACD856, the first potentially disease-modifying, small-molecule drug designed to enhance neurotrophic factor signaling, targeting pathways crucial for neuronal survival and cognitive function. ACD856 has shown promising results in preclinical studies, demonstrating its ability to improve cognitive function and promote neuronal health. Phase I clinical trial has confirmed its safety and initial efficacy, laying the groundwork for more extensive studies. The proposed project focuses on advancing ACD856 through a Phase IIa clinical study, aiming to confirm its efficacy and safety in a larger patient population. This study, planned for 2025-2026, will reduce the risks associated with further development, facilitating additional funding and partnerships for Phase III trials and market entry. The development of ACD856 offers significant benefits. For patients, it could improve cognitive function and slow disease progression, enhancing quality of life and prolonging independence. For caregivers, it can reduce responsibilities and emotional stress. For healthcare systems, delayed AD progression could reduce the need for long-term care. By aligning with EU health policies prioritizing innovative treatments for chronic diseases, ACD856 has the potential to transform AD treatment, benefiting millions of patients, caregivers, and healthcare systems across Europe.

Keywords: alzheimer s disease neurodegeneration small molecule drug neuroprotection cognitive enhancement
Metol: next-generation thermoplastic composites for sustainable, high-performing hydrogen infrastructure (METOL)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: United Kingdom
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 892500.0
EU funding (EUR): 892500.0
Participants: 1
Project status: SIGNED

Fibre-reinforced plastic composites are strong, durable and lightweight, and have revolutionised multiple industries. Thermoset composites dominate the market due to their relative ease of processing, but they are not easily recycled, leading to significant end-of-life and disposal challenges. Fully melt-reprocessable thermoplastic composites offer a sustainable alternative. However, market traction has been slow as most thermoplastics exhibit high melt viscosities, which hinders reinforcing fibre impregnation and subsequently limits performance. To address this, HIVE has developed a low-melt viscosity (<40cP) thermoplastic (Metol) that can be used in conventional thermoset processing techniques, enabling development of high-fibre volume fraction composites (<70%) with high-level mechanical and physical properties. Uniquely, Metol™ composites can be returned to their base materials (thermoplastic resin+reinforcing fibres) via solvolysis for re-use in other applications without degradation. In this project, HIVE will develop the established pultrusion technique, exchanging conventional thermoset materials for Metol, to provide sustainable, high-performance, and cost-efficient manufacture of fibre-reinforced tape for thermoplastic composite pipes and pressure vessels to meet the growing demand for hydrogen distribution and storage as Europe transitions to a carbon-neutral economy. Current solutions struggle with embrittlement, slow lay-down, and high CO2 emissions (steel) and limited recyclability (thermosets). Metol will overcome these issues to provide the in-demand infrastructure at reduced cost and with lower CO2 emissions, whilst supporting sector transition towards a circular economy, offering superior recycling and repurposing. Successful project delivery will establish HIVE as market leader in the development of disruptive technologies in the thermoplastic composite and tape sectors, unlocking opportunities to revolutionise secondary markets in the future.

Keywords: composites thermoplastics sustainability hydrogen pipeline tape infrastructure
Fight Against Large-scale Corruption and Organised Crime Networks (FALCON)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Civil Security for Society
Theme: Civil Security for Society
Destination: Fighting Crime and Terrorism
Action type: Innovation actions
Countries involved: Greece,Germany,Lithuania,Italy,Spain,France,Sweden,Poland,Moldova, Republic of,Serbia,Bulgaria,Romania,United Kingdom,Switzerland,Hungary
Call: Effective fight against corruption (HORIZON-CL3-2022-FCT-01, 2022)
Start date: 2023-09-01
End date: 2026-08-31
Duration (months): 36.0
Total project cost (EUR): 5080455.0
EU funding (EUR): 4720938.0
Participants: 27
Project status: SIGNED

Current evidence suggests that the global fight against corruption faces serious challenges: policy decisions are not well informed, the corruption landscape is complex and enormous, while measuring corruption is so far mostly based on subjective approaches, and there is lack of appropriate technological tools to support anti-corruption. To address these challenges, FALCON is designed and dedicated to support the composition, update and management of comprehensive corruption intelligence pictures, within domains and jurisdictions of interest. This will be accomplished following a multi-actor, evidence-based, data-driven approach, building upon existing assets and prior work of consortium partners. FALCON will, first, develop and validate objective and actionable indicators (individual and composite) of corruption that can be used to inform policy decisions. Second, it will design, implement and integrate powerful data analytics tools, data pipelines and applications that support the management of the entire lifecycle of corruption intelligence pictures. This will enable comprehensive corruption risk assessment, informed policy making, and improved anticorruption law enforcement. FALCON will be piloted in four corruption domains – corruption schemes at border crossings, sanction circumvention by kleptocrats/oligarchs, public procurement fraud, conflicts of interest of politically exposed persons (PEPs) – involving law enforcement experts (police authorities and border guards) from six (6) European countries and other key actors (i.e., GovTech providers, academia, financial intermediaries, policy makers, NGOs, and civil society). FALCON’s implementation will be incremental and iterative, forming synergies between SSH and technological expertise, and will adhere to the principles of Trustworthy AI and responsible research and innovation. Lastly, FALCON has defined specific key exploitable results and performance indicators for measuring its progress and success.

Keywords: corruption risk assessment,corruption detection,corruption indices,natural language processing,semantic reasoning,artificial intelligence,machine learning